Who are FKB327's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): IBI310, IBI363, AK104(IV), AK102, BAT2506 injection, BAT2306.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fkb327.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

FKB327 — Competitive Intelligence Brief

FKB327 (FKB327) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific checkpoint inhibitor. Area: Oncology.

phase 3 Bispecific checkpoint inhibitor PD-L1 and CEACAM1 (TIM-3 ligand) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

FKB327 (FKB327) — Fujifilm Kyowa Kirin Biologics Co., Ltd.. FKB327 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T-cell responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
FKB327 TARGET	FKB327	Fujifilm Kyowa Kirin Biologics Co., Ltd.	phase 3	Bispecific checkpoint inhibitor	PD-L1 and CEACAM1 (TIM-3 ligand)
IBI310	IBI310	Innovent Biologics (Suzhou) Co. Ltd.	phase 3	Bispecific checkpoint inhibitor	PD-1 and TIM-3
IBI363	IBI363	Innovent Biologics (Suzhou) Co. Ltd.	phase 3	Bispecific checkpoint inhibitor	PD-1 and TIM-3
AK104(IV)	AK104(IV)	Akeso	phase 3	Bispecific checkpoint inhibitor	PD-1 and TIM-3
AK102	AK102	Akeso	phase 3	Bispecific checkpoint inhibitor	PD-1 and CTLA-4
BAT2506 injection	BAT2506 injection	Bio-Thera Solutions	phase 3	Bispecific checkpoint inhibitor
BAT2306	BAT2306	Bio-Thera Solutions	phase 3	Bispecific checkpoint inhibitor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific checkpoint inhibitor class)

Akeso · 3 drugs in this class
Bio-Thera Solutions · 3 drugs in this class
Innovent Biologics (Suzhou) Co. Ltd. · 2 drugs in this class
Fujifilm Kyowa Kirin Biologics Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FKB327 — Competitive Intelligence Brief. https://druglandscape.com/ci/fkb327. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab